F-star Therapeutics, Inc. Common Stock
FSTX
FSTX was delisted on the 8th of March, 2023.
21 hedge funds and large institutions have $14.1M invested in F-star Therapeutics, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 11 reducing their positions, and 7 closing their positions.
258% more capital invested
Capital invested by funds: $3.96M → $14.1M (+$10.2M)
9% less funds holding
Funds holding: 23 → 21 (-2)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
73% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AVA
Atlas Venture Advisors
Boston,
Massachusetts
|
+$3.76M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.85M |
| 3 |
Renaissance Technologies
New York
|
+$344K |
| 4 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$228K |
| 5 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$134K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$1.37M |
| 2 |
TA
Tiedemann Advisors
New York
|
-$481K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$84K |
| 4 |
Bank of New York Mellon
New York
|
-$60K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$27K |
FSTX Hedge Fund Activity: Q4 2020 in Review
21 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in F-star Therapeutics, Inc. Common Stock (FSTX) for Q4 2020, worth a combined $14.1M — up 258% from $3.96M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of FSTX and 5 opened new positions — a net loss of 2 holders — while 11 trimmed existing stakes and 3 added.
The largest buyer was Atlas Venture Advisors, opening a new position worth an estimated $3.76M. The largest seller was BVF Inc, cutting an estimated $1.37M.
- 21 institutional investors held F-star Therapeutics, Inc. Common Stock (FSTX) as of Q4 2020, down from 23 in Q3 2020.
- Funds reported $14.1M of F-star Therapeutics, Inc. Common Stock stock for Q4 2020, up 258% quarter-over-quarter.
- 5 funds opened new F-star Therapeutics, Inc. Common Stock positions in Q4 2020 and 7 closed out, a net change of -2 holders.
- The largest F-star Therapeutics, Inc. Common Stock buyer in Q4 2020 was Atlas Venture Advisors, an estimated $3.76M added.
- The largest F-star Therapeutics, Inc. Common Stock seller in Q4 2020 was BVF Inc, an estimated $1.37M sold.
Based on aggregated 13F filings for Q4 2020.